(Q37461371)

20 August 2017

1 reference

title

Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects (English)

1 reference

20 August 2017

1 reference

4

Jaap Goudsmit

1 reference

20 August 2017

3

Angelique Lemckert

1 reference

20 August 2017

Katarina Radosević

1

1 reference

20 August 2017

Ariane Rodriguez

series ordinal

2

1 reference

20 August 2017

publication date

1 May 2009

1 reference

Expert Review of Vaccines

20 August 2017

published in

1 reference

20 August 2017

volume

8

1 reference

20 August 2017

issue

5

1 reference

20 August 2017

page(s)

577-592

1 reference

Protective 'immunity' by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called 'immunological memory'.

20 August 2017

cites work

1 reference

Vaccines: correlates of vaccine-induced immunity

21 January 2018

1 reference

Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know

21 January 2018

1 reference

Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections

21 January 2018

1 reference

T-cell quality in memory and protection: implications for vaccine design

21 January 2018

1 reference

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

21 January 2018

1 reference

Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys

21 January 2018

1 reference

Advancing TB vaccines to Phase I clinical trials in the US: regulatory/manufacturing/licensing issues

21 January 2018

1 reference

XDR Tuberculosis — Implications for Global Public Health

21 January 2018

1 reference

Envisioning future strategies for vaccination against tuberculosis.

21 January 2018

1 reference

Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis

21 January 2018

1 reference

High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection

21 January 2018

1 reference

Early T-cell responses in tuberculosis immunity

21 January 2018

1 reference

Persistence of the immune response induced by BCG vaccination

21 January 2018

1 reference

A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers

21 January 2018

1 reference

Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin

21 January 2018

1 reference

Advances in tuberculosis vaccine strategies

21 January 2018

1 reference

Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis

21 January 2018

1 reference

Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin

21 January 2018

1 reference

Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs

21 January 2018

1 reference

Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon

21 January 2018

1 reference

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials

21 January 2018

1 reference

New TB vaccine granted orphan drug status

21 January 2018

1 reference

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

21 January 2018

1 reference

Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations

21 January 2018

1 reference

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa

21 January 2018

1 reference

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa

21 January 2018

1 reference

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

21 January 2018

1 reference

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

21 January 2018

1 reference

Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa

21 January 2018

1 reference

rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector

21 January 2018

1 reference

Tuberculosis vaccine development; from mouse to man.

21 January 2018

1 reference

Tuberculosis vaccines - an update.

21 January 2018

1 reference

Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model

21 January 2018

1 reference

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.

21 January 2018

1 reference

Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites

21 January 2018

1 reference

Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children

21 January 2018

1 reference

Protective CD8 T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response.

21 January 2018

1 reference

Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria

21 January 2018

1 reference

21 January 2018

RTS,S/AS02A for malaria

1 reference

Structure of the Gene Encoding the Immunodominant Surface Antigen on the Sporozoite of the Human Malaria Parasite Plasmodium falciparum

21 January 2018

1 reference

The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites

21 January 2018

1 reference

Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial

21 January 2018

1 reference

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

21 January 2018

1 reference

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

21 January 2018

1 reference

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

21 January 2018

1 reference

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

21 January 2018

1 reference

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research

21 January 2018

1 reference

Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates

21 January 2018

1 reference

Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial

21 January 2018

1 reference

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

21 January 2018

1 reference

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis

21 January 2018

1 reference

Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone

21 January 2018

1 reference

Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area

21 January 2018

1 reference

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.

21 January 2018

1 reference

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

21 January 2018

1 reference

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

21 January 2018

1 reference

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

21 January 2018

1 reference

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

21 January 2018

1 reference

Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

21 January 2018

1 reference

Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein

21 January 2018

1 reference

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

21 January 2018

1 reference

Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.

21 January 2018

1 reference

Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei

21 January 2018

1 reference

Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1

21 January 2018

1 reference

Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice

21 January 2018

1 reference

Setting the stage: host invasion by HIV.

21 January 2018

1 reference

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells

21 January 2018

1 reference

Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases.

21 January 2018

1 reference

An HIV vaccine--evolving concepts

21 January 2018

1 reference

HIV vaccine design: insights from live attenuated SIV vaccines

21 January 2018

1 reference

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

21 January 2018

1 reference

Antibody-based HIV-1 vaccines: recent developments and future directions

21 January 2018

1 reference

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene

21 January 2018

1 reference

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

21 January 2018

1 reference

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates

21 January 2018

1 reference

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag

21 January 2018

1 reference

DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles

21 January 2018

1 reference

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells

21 January 2018

1 reference

Public health. A sound rationale needed for phase III HIV-1 vaccine trials

21 January 2018

1 reference

Policy rebuttal. HIV vaccine trial justified.

21 January 2018

1 reference

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c

21 January 2018

1 reference

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

21 January 2018

1 reference

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

21 January 2018

1 reference

Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques.

21 January 2018

1 reference

A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1.

21 January 2018

1 reference

Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines: implications for future trials

21 January 2018

1 reference

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

21 January 2018

1 reference

Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge

21 January 2018

1 reference

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

21 January 2018

1 reference

Challenges in the development of an HIV-1 vaccine

21 January 2018

1 reference

Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication

21 January 2018

1 reference

Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans

21 January 2018

1 reference

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D

21 January 2018

1 reference

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

21 January 2018

1 reference

Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes

21 January 2018

1 reference

Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homing

21 January 2018

1 reference

Towards a crucial role for DC-SIGN in tuberculosis and beyond

21 January 2018

1 reference

Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.09.14

1 reference

20 August 2017

1 reference